{"hands_on_practices": [{"introduction": "A cornerstone of managing Age-related Macular Degeneration is accurately assessing a patient's risk of progression to advanced, vision-threatening stages. This practice allows you to apply the widely used Age-Related Eye Disease Study (AREDS) simplified scoring system, a fundamental tool for clinical decision-making and patient counseling. By converting clinical findings into a quantitative risk estimate, you will hone the essential skill of prognosticating disease course based on funduscopic examination [@problem_id:4650558].", "problem": "A patient is seen with age-related macular degeneration (AMD) in both eyes. On dilated fundus examination of each eye, there are large drusen with diameter $\\geq 125 \\ \\mu \\mathrm{m}$ and definite pigmentary abnormalities in the macula. There are no signs of advanced age-related macular degeneration (geographic atrophy involving the foveal center or neovascular AMD) in either eye.\n\nUse the Age-Related Eye Disease Study (AREDS) simplified severity scale, defined as follows: for each eye, assign $1$ point for the presence of large drusen and $1$ point for the presence of definite pigmentary abnormalities; if advanced age-related macular degeneration is present in an eye, that eye contributes $2$ points. The total AREDS simplified score is the sum across both eyes and ranges from $0$ to $4$.\n\nAssume the following risk model for $5$-year progression to advanced age-related macular degeneration: when the total AREDS simplified score is $s=0$, the baseline $5$-year absolute risk is $p_0=0.005$. For each one-point increase in the total score, the $5$-year odds of progression are multiplied by a constant factor $\\theta=4$.\n\nBased on these assumptions and the examination findings, compute the patientâ€™s total AREDS simplified score $s$ and then compute the corresponding absolute $5$-year risk of progression. Round your answer to $4$ significant figures. Express the final risk as a decimal fraction with no percent sign. Provide only the risk value as your final answer.", "solution": "The problem is valid as it is scientifically grounded in the principles of clinical ophthalmology and biostatistics, specifically using the well-established Age-Related Eye Disease Study (AREDS) framework. The problem is well-posed, objective, and provides all necessary information to compute a unique solution.\n\nThe solution process consists of two main steps: first, determining the patient's total AREDS simplified score based on the provided clinical findings, and second, using the given risk model to calculate the $5$-year absolute risk of progression to advanced age-related macular degeneration (AMD).\n\n**Step 1: Calculation of the Total AREDS Simplified Score ($s$)**\n\nThe AREDS simplified severity scale is defined by assigning points to each eye based on specific findings. The total score, $s$, is the sum of points from both eyes.\n\nFor the right eye:\n- The presence of large drusen with a diameter $\\geq 125 \\ \\mu \\mathrm{m}$ contributes $1$ point.\n- The presence of definite pigmentary abnormalities contributes $1$ point.\n- The problem explicitly states there are no signs of advanced AMD, so the rule for advanced AMD (which would assign $2$ points) does not apply.\nThe score for the right eye is therefore $1 + 1 = 2$.\n\nFor the left eye:\n- The problem states that the findings are present in \"both eyes\", so the condition of the left eye is identical to the right eye.\n- The presence of large drusen contributes $1$ point.\n- The presence of definite pigmentary abnormalities contributes $1$ point.\n- There are no signs of advanced AMD.\nThe score for the left eye is also $1 + 1 = 2$.\n\nThe total AREDS simplified score, $s$, is the sum of the scores from both eyes:\n$$s = (\\text{score for right eye}) + (\\text{score for left eye}) = 2 + 2 = 4$$\n\n**Step 2: Calculation of the 5-Year Absolute Risk of Progression**\n\nThe problem provides a risk model based on odds. The relationship between probability, $p$, and odds, $O$, is given by:\n$$O = \\frac{p}{1-p} \\quad \\text{and} \\quad p = \\frac{O}{1+O}$$\n\nFirst, we determine the baseline odds of progression, $O_0$, corresponding to a total score of $s=0$. The baseline $5$-year absolute risk is given as $p_0 = 0.005$.\n$$O_0 = \\frac{p_0}{1-p_0} = \\frac{0.005}{1-0.005} = \\frac{0.005}{0.995}$$\n\nThe model states that for each one-point increase in the total score, the $5$-year odds of progression are multiplied by a constant factor $\\theta = 4$. This implies an exponential relationship between the odds and the score:\n$$O_s = O_0 \\cdot \\theta^s$$\nwhere $O_s$ is the odds of progression for a patient with a total score of $s$.\n\nFor this patient, the total score is $s=4$. We can now calculate the corresponding odds of progression, $O_4$:\n$$O_4 = O_0 \\cdot \\theta^4 = \\left( \\frac{0.005}{0.995} \\right) \\cdot 4^4$$\nSince $4^4 = 256$, we have:\n$$O_4 = \\frac{0.005 \\times 256}{0.995} = \\frac{1.28}{0.995}$$\n\nNow, we convert these odds back to a probability (absolute risk), $p_4$:\n$$p_4 = \\frac{O_4}{1+O_4} = \\frac{\\frac{1.28}{0.995}}{1 + \\frac{1.28}{0.995}}$$\nTo simplify this complex fraction, we multiply the numerator and denominator by $0.995$:\n$$p_4 = \\frac{1.28}{0.995 + 1.28} = \\frac{1.28}{2.275}$$\n\nPerforming the final division:\n$$p_4 \\approx 0.56263736...$$\n\nThe problem requires rounding the final answer to $4$ significant figures.\nThe first four significant figures are $5$, $6$, $2$, and $6$. The fifth significant figure is $3$, which is less than $5$, so we round down (i.e., we do not change the fourth digit).\n$$p_4 \\approx 0.5626$$\nThis is the patient's absolute $5$-year risk of progression to advanced AMD.", "answer": "$$\n\\boxed{0.5626}\n$$", "id": "4650558"}, {"introduction": "Effective management of neovascular AMD requires quantitatively monitoring the response to therapies like anti-VEGF injections. This exercise challenges you to connect anatomical changes, measured by Optical Coherence Tomography (OCT), with functional outcomes in visual acuity. By using a hypothetical but plausible model linking central subfield thickness reduction to expected letter score gains, you will practice interpreting treatment efficacy and develop a deeper appreciation for the structure-function relationship in the macula [@problem_id:4650626].", "problem": "A patient with neovascular age-related macular degeneration (AMD) undergoes three consecutive monthly intravitreal injections of anti-Vascular Endothelial Growth Factor (anti-VEGF). Optical Coherence Tomography (OCT) shows a baseline central subfield thickness (CST) of $420\\,\\mu\\text{m}$ decreasing to $320\\,\\mu\\text{m}$ at the three-month visit. Baseline best-corrected visual acuity is $0.6$ in logarithm of the minimum angle of resolution (logMAR).\n\nUse the following foundational elements:\n- By definition, the fractional reduction in a biomarker from baseline is the ratio of the absolute decrease to the baseline value. Let the fractional CST reduction be $r = \\dfrac{\\text{CST}_{\\text{baseline}} - \\text{CST}_{\\text{post}}}{\\text{CST}_{\\text{baseline}}}$, and express $r$ as a decimal (do not use a percent sign).\n- Early Treatment Diabetic Retinopathy Study (ETDRS) letter scores are commonly used to quantify visual acuity changes, and for small changes, the ETDRS scale is approximately linear with logMAR: a change of $5$ letters corresponds to $0.1$ logMAR, so $1$ letter corresponds to $0.02$ logMAR.\n- Empirically, the expected functional gain attributable to reduction in macular thickening follows a diminishing-returns relationship modulated by photoreceptor integrity. Model the expected ETDRS letter gain from CST change as\n$$\n\\Delta L \\;=\\; L_{\\max}\\,\\frac{\\Delta \\text{CST}}{K + \\Delta \\text{CST}}\\,M,\n$$\nwhere $\\Delta \\text{CST} = \\text{CST}_{\\text{baseline}} - \\text{CST}_{\\text{post}}$, $L_{\\max} = 8$ letters represents the maximal mean gain from fluid resolution alone, $K = 150\\,\\mu\\text{m}$ is a half-saturation constant reflecting diminishing returns, and $M = 0.75$ is a photoreceptor integrity factor (unitless, between $0$ and $1$) summarizing ellipsoid zone continuity at baseline.\n\nAssuming no other limiting factors, compute the fractional CST reduction $r$ and use the above definitions to derive the predicted post-treatment visual acuity in logMAR at three months. Express the final visual acuity in logMAR and round your answer to four significant figures.", "solution": "The problem is deemed valid as it is scientifically grounded in established ophthalmological concepts, is well-posed with all necessary information provided, and is expressed in objective, quantitative terms. The model provided is a plausible biophysical representation of a stimulus-response relationship with diminishing returns. All data are consistent and realistic for the clinical scenario described.\n\nThe solution proceeds by following the sequence of calculations defined in the problem statement.\n\nFirst, we calculate the fractional reduction in central subfield thickness (CST), denoted by $r$. The given values are the baseline CST, $\\text{CST}_{\\text{baseline}} = 420\\,\\mu\\text{m}$, and the post-treatment CST, $\\text{CST}_{\\text{post}} = 320\\,\\mu\\text{m}$.\nThe formula for fractional reduction is:\n$$\nr = \\frac{\\text{CST}_{\\text{baseline}} - \\text{CST}_{\\text{post}}}{\\text{CST}_{\\text{baseline}}}\n$$\nSubstituting the given values:\n$$\nr = \\frac{420 - 320}{420} = \\frac{100}{420} = \\frac{5}{21}\n$$\nAs a decimal, this is approximately $r \\approx 0.238095...$.\n\nNext, we compute the predicted post-treatment visual acuity. This requires calculating the expected gain in Early Treatment Diabetic Retinopathy Study (ETDRS) letters, $\\Delta L$, based on the reduction in CST. The model for this is:\n$$\n\\Delta L = L_{\\max}\\,\\frac{\\Delta \\text{CST}}{K + \\Delta \\text{CST}}\\,M\n$$\nThe absolute change in CST, $\\Delta \\text{CST}$, is the numerator of the fraction for $r$:\n$$\n\\Delta \\text{CST} = \\text{CST}_{\\text{baseline}} - \\text{CST}_{\\text{post}} = 420\\,\\mu\\text{m} - 320\\,\\mu\\text{m} = 100\\,\\mu\\text{m}\n$$\nThe given parameters for the model are:\n- Maximal mean gain, $L_{\\max} = 8$ letters.\n- Half-saturation constant, $K = 150\\,\\mu\\text{m}$.\n- Photoreceptor integrity factor, $M = 0.75$.\n\nSubstituting these values into the model for $\\Delta L$:\n$$\n\\Delta L = 8 \\cdot \\frac{100}{150 + 100} \\cdot 0.75\n$$\n$$\n\\Delta L = 8 \\cdot \\frac{100}{250} \\cdot 0.75\n$$\n$$\n\\Delta L = 8 \\cdot (0.4) \\cdot (0.75) = 3.2 \\cdot 0.75 = 2.4 \\text{ letters}\n$$\nSo, the predicted functional gain is $2.4$ ETDRS letters.\n\nThe next step is to convert this letter gain into a change in the logarithm of the minimum angle of resolution (logMAR) score. An improvement in vision (a gain in letters) corresponds to a decrease in the logMAR score. The problem states that a change of $1$ letter corresponds to $0.02$ logMAR. Therefore, the change in logMAR acuity, $\\Delta \\text{VA}_{\\text{logMAR}}$, is:\n$$\n\\Delta \\text{VA}_{\\text{logMAR}} = -(\\Delta L \\times 0.02)\n$$\n$$\n\\Delta \\text{VA}_{\\text{logMAR}} = -(2.4 \\times 0.02) = -0.048\n$$\nThe negative sign correctly indicates an improvement in visual acuity.\n\nFinally, we calculate the predicted post-treatment visual acuity, $\\text{VA}_{\\text{post}}$, by applying this change to the baseline acuity, $\\text{VA}_{\\text{baseline}} = 0.6$ logMAR.\n$$\n\\text{VA}_{\\text{post}} = \\text{VA}_{\\text{baseline}} + \\Delta \\text{VA}_{\\text{logMAR}}\n$$\n$$\n\\text{VA}_{\\text{post}} = 0.6 + (-0.048) = 0.6 - 0.048 = 0.552\n$$\nThe problem requires the final answer to be rounded to four significant figures. The calculated value is $0.552$. To express this with four significant figures, we add a trailing zero: $0.5520$.", "answer": "$$\n\\boxed{0.5520}\n$$", "id": "4650626"}, {"introduction": "Progress in treating AMD is driven by well-designed clinical trials, and understanding their architecture is a critical skill for any clinician-scientist. This exercise moves from patient-level data to the principles of study design by focusing on sample size calculation, a pivotal step in ensuring a trial has adequate statistical power. By determining the number of participants needed to detect a clinically meaningful treatment effect, you will gain hands-on experience with the statistical foundations of evidence-based medicine [@problem_id:4650581].", "problem": "A randomized, double-masked, parallel-group clinical trial is planned to compare two intravitreal treatment regimens for neovascular age-related macular degeneration (AMD). The primary endpoint is the mean change from baseline in best-corrected visual acuity (BCVA) measured in Early Treatment Diabetic Retinopathy Study (ETDRS) letters at $12$ months. Investigators regard a true between-group mean difference of $\\delta = 5$ ETDRS letters as clinically meaningful. Prior data suggest that the change scores in each arm are approximately Gaussian with a common standard deviation $\\sigma = 10$ ETDRS letters. Allocation will be $1{:}1$. A two-sided hypothesis test of $H_{0}: \\mu_{1} - \\mu_{2} = 0$ will be used with Type I error rate $\\alpha = 0.05$, and the desired power is $1 - \\beta = 0.8$. Assume independence between arms, normality of the mean change, known and equal variance across arms, and use the large-sample Wald $Z$-test for the difference in means.\n\nStarting from the sampling distribution of the difference in independent Gaussian means and the definitions of Type I and Type II errors for a two-sided test, derive the minimal equal per-arm sample size required to achieve the specified power to detect the targeted mean difference. Express the final per-arm sample size as the smallest integer $n$ that satisfies the power criterion (i.e., apply the ceiling function to the computed real-valued solution). Do not inflate for attrition. Provide the final per-arm sample size as a single number without units.", "solution": "Under the model assumptions, let $X_{1,1}, \\dots, X_{1,n}$ be the change scores in arm $1$ and $X_{2,1}, \\dots, X_{2,n}$ in arm $2$, with $X_{1,i} \\stackrel{\\text{iid}}{\\sim} \\mathcal{N}(\\mu_{1}, \\sigma^{2})$ and $X_{2,j} \\stackrel{\\text{iid}}{\\sim} \\mathcal{N}(\\mu_{2}, \\sigma^{2})$, independent across arms. The sample means satisfy $\\bar{X}_{1} \\sim \\mathcal{N}(\\mu_{1}, \\sigma^{2}/n)$ and $\\bar{X}_{2} \\sim \\mathcal{N}(\\mu_{2}, \\sigma^{2}/n)$, independent. Therefore, the difference $D = \\bar{X}_{1} - \\bar{X}_{2}$ has distribution\n$$\nD \\sim \\mathcal{N}\\!\\left(\\mu_{1} - \\mu_{2}, \\frac{\\sigma^{2}}{n} + \\frac{\\sigma^{2}}{n}\\right) = \\mathcal{N}\\!\\left(\\mu_{1} - \\mu_{2}, \\frac{2\\sigma^{2}}{n}\\right).\n$$\nDefine the standard error $SE = \\sqrt{2\\sigma^{2}/n} = \\sigma \\sqrt{2/n}$. The two-sided Wald $Z$-test rejects $H_{0}: \\mu_{1} - \\mu_{2} = 0$ when $|D| \\ge z_{1-\\alpha/2} \\, SE$, where $z_{q}$ denotes the $q$-quantile of the standard normal distribution.\n\nPower is $1 - \\beta = \\mathbb{P}(\\text{reject } H_{0} \\mid \\mu_{1} - \\mu_{2} = \\delta)$ for the targeted true effect $\\delta = 5$. With $\\delta > 0$, a sufficient (conservative for two-sided testing) condition for achieving the desired power is to require\n$$\n\\mathbb{P}\\!\\left(D \\ge z_{1-\\alpha/2} \\, SE \\,\\middle|\\, \\mu_{1} - \\mu_{2} = \\delta \\right) \\;=\\; 1 - \\beta.\n$$\nStandardizing using $Z = (D - \\delta)/SE \\sim \\mathcal{N}(0,1)$ under the alternative yields\n$$\n\\mathbb{P}\\!\\left(Z \\ge \\frac{z_{1-\\alpha/2} \\, SE - \\delta}{SE} \\right) = 1 - \\beta\n\\;\\;\\Longleftrightarrow\\;\\;\n\\frac{z_{1-\\alpha/2} \\, SE - \\delta}{SE} = z_{1-\\beta}.\n$$\nSolving for $n$ gives\n$$\n\\frac{\\delta}{SE} = z_{1-\\alpha/2} + z_{1-\\beta}\n\\;\\;\\Longleftrightarrow\\;\\;\n\\frac{\\delta}{\\sigma \\sqrt{2/n}} = z_{1-\\alpha/2} + z_{1-\\beta}\n\\;\\;\\Longleftrightarrow\\;\\;\nn = \\frac{2\\sigma^{2}\\,\\big(z_{1-\\alpha/2} + z_{1-\\beta}\\big)^{2}}{\\delta^{2}}.\n$$\n\nNow substitute the design parameters $\\alpha = 0.05$, $1 - \\beta = 0.8$ (so $\\beta = 0.2$), $\\sigma = 10$, and $\\delta = 5$. The relevant normal quantiles are $z_{1-\\alpha/2} = z_{0.975} \\approx 1.959963984$ and $z_{1-\\beta} = z_{0.8} \\approx 0.841621234$.\nCompute\n$$\nz_{1-\\alpha/2} + z_{1-\\beta} \\approx 1.959963984 + 0.841621234 \\approx 2.801585218,\n$$\n$$\n\\big(z_{1-\\alpha/2} + z_{1-\\beta}\\big)^{2} \\approx (2.801585218)^{2} \\approx 7.848877.\n$$\nTherefore,\n$$\nn \\approx \\frac{2 \\times (10)^{2} \\times 7.848877}{(5)^{2}} \\;=\\; \\frac{200 \\times 7.848877}{25} \\;=\\; 8 \\times 7.848877 \\;\\approx\\; 62.790996.\n$$\nThe minimal equal per-arm sample size is obtained by applying the ceiling function to ensure the power criterion is met:\n$$\nn_{\\text{per arm}} = \\lceil 62.790996 \\rceil = 63.\n$$\nThus, the required per-arm sample size is $63$ participants.", "answer": "$$\\boxed{63}$$", "id": "4650581"}]}